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Objectives/Hypothesis: To determine if the various imaging modalities for distant metastasis (DM) diagnosis alters life
expectancy in head and neck squamous cell carcinoma (HNSCC).
Study Design: Retrospective.
Methods: One hundred seventy patients (mean age, 59.1 years; male:female, 135:35) with HNSCC who developed DM
were reviewed. The main outcome measures were the method of DM diagnosis and time from DM diagnosis to death while
controlling for clinical parameters (age, gender, tobacco status, primary tumor site, initial TNM classification, number and site
of DM, administration of palliative chemotherapy).
Results: Tumor subsites were: 40 oral cavity, 75 oropharynx, 36 larynx, 10 hypopharynx, one nasopharynx, and eight
unknown primary. Of the patients, 16.5% (28/170) had distant metastasis at presentation; the remaining 142 patients were
diagnosed with DM at a median of 324 days from diagnosis. Although patients diagnosed with DM by positron-emission
tomography (PET) scan were more likely to have multiple DM sites (P ¼ .0001), there were no differences in life expectancy
in patients who were diagnosed with or without PET scan (median, 185 vs. 165 days, P ¼ .833). There were no differences in
life expectancy based on age, gender, site of primary tumor, or number/site of DM. The use of palliative chemotherapy
resulted in a significantly longer life expectancy (median, 285 vs. 70 days; P ¼ .001).
Conclusions: Although a PET scan is more likely to diagnose multiple DM sites, there was no difference in life expect-
ancy based on imaging modality. Patients who are symptomatic from their distant metastasis have a worse life expectancy,
and palliative chemotherapy was able to increase life expectancy, even in patients who were symptomatic from the distant
metastasis.
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INTRODUCTION
Distant metastasis from squamous cell carcinoma of
the head and neck (HNSCC) affords an extremely poor
prognosis.1,2 The detection of distant metastasis is an
integral part of determining treatment options and
appropriate patient counseling. The choice of diagnostic
modality for the detection of distant metastasis, has
historically included chest x-ray (CXR) or computed
tomography (CT). Over the past 10 years, positron-emis-
sion tomography (PET) has seen broad adoption across
HNSCC subsites for its use in screening and surveillance.
There are recent reports that suggest PET imaging is
more sensitive at identifying occult metastatic disease
than other radiographic modalities, such as CT or mag-
netic resonance imaging (MRI).3 However, it is unclear
whether detection of distant metastasis by this method
has influenced the number or site of metastasis or influ-
enced life expectancy in patients with HNSCC.
The purpose of this study was to determine if the
various imaging modalities used to diagnose distant me-
tastasis alters life expectancy in HNSCC and to identify
factors, if any, that improve life expectancy.
MATERIALS AND METHODS
Study Population
This study was a retrospective review of patients who had
pathologically confirmed HNSCC diagnosed between 1997 and
2010 and developed distant metastasis either at presentation or
during the course of their care. Patient identification and data
collection were conducted through our University of Michigan
Specialized Program of Research Excellence (SPORE) database
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and confirmed through the electronic medical records. All
patients were staged based on the 2002 American Joint Com-
mittee on Cancer staging system and provided written informed
consent to participate in the University of Michigan SPORE
program, which was approved by the institutional review board.
Population Characteristics
There were 170 patients who were identified as having
distant metastasis during the course of head and neck cancer
treatment; baseline clinical characteristics are shown in Table I.
There were 135 (79%) male patients and the average age at ini-
tial diagnosis was 59.1 years. Stratification by subsites revealed
40 (24%) oral cavity, 75 (44%) oropharynx, 36 (21%) larynx, 10
(6%) hypopharynx, one (1%) nasopharynx, and eight (5%)
unknown primary tumors. There were 28 (16%) patients who
presented with distant metastasis; the remaining 142 (84%)
patients were diagnosed with distant metastasis during the
course of their care at a median of 381 days from head and
neck cancer diagnosis. There were 164 (96%) patients with
stage III or IV disease at the time of their initial diagnosis.
Chemotherapy was used in 110 (65%) patients for either pri-
mary concurrent therapy with radiation or for adjuvant
treatment after surgical extirpation. Tobacco status was defined
categorically as never, prior (quit >6 months ago), or current
use of cigarettes, cigars, pipe, chewing tobacco, snuff, or snus.
There were 20 (12%) never tobacco users, 57 (34%) prior tobacco
users, and 93 (55%) current tobacco users at initial diagnosis.
Diagnosis of Distant Metastasis
The diagnosis of distant metastasis was defined by a
radiologic or clinical finding that was considered by the treating
physician to be metastatic disease. Histologic confirmation was
not always necessary at the discretion of the treating physician.
The imaging modality first identifying distant metastasis was
recorded along with the date and site(s) of disease. The reason
for the treating physician to order any imaging modality was
recorded and for analysis purposes was divided into two catego-
ries: surveillance imaging or symptomatic imaging. If patients
had more than one imaging modality identifying distant
metastatic sites, the first imaging modality was considered to
have obtained the diagnosis. All sites of distant metastasis were
considered to be present at the initial date of distant metastatic
diagnosis (i.e., if a patient had a chest x-ray showing metastatic
disease, followed by a chest CT showing chest and liver metas-
tasis, the modality that obtained the diagnosis would be chest
x-ray, and metastasis to the lung and liver were recorded).
Patients with distant metastasis found within 30 days of initial
head and neck cancer diagnosis were considered to have distant
metastasis at presentation.
Statistical Analysis
The main outcome measures were the method of distant
metastasis diagnosis and time from distant metastasis diagnosis
to death (life expectancy) while examining clinical parameters
(age, gender, tobacco status, primary tumor site, initial TNM
classification, number and site of distant metastasis, presence
of symptoms attributed to distant metastasis, and administra-
tion of palliative chemotherapy). Patients who were alive with
disease were censored on the date of their last clinical visit in
any department. Patients with no evidence of disease were cen-
sored on the last date of their clinical visit in otolaryngology,
radiation oncology, or medical oncology.
Survival estimates were computed using the Kaplan-Meier
method and were defined from the date of distant metastasis
diagnosis to date of censorship (death, last follow-up). Univari-
ate and bivariate Cox regression models were used to test the
association of clinical parameters with decreased survival time
independent of other tested variables. The v2 and Fischer exact
tests were used to determine the relationship between the type
of imaging modality and the site (single versus multiple) of
TABLE I.
Baseline Characteristics of Patients Who Developed Distant Me-
tastasis in Head and Neck Squamous Cell Carcinoma.
Characteristics
Patients Who
Developed Distant
Metastasis, N ¼ 170
Age, mean (SD), yr 59.1 (10.6)
Subsite, % (no.)
Oral Cavity 23.5 (40)
Oropharnyx 44.1 (75)
Larynx 21.2 (36)
Hypopharynx 5.9 (10)
Nasopharnyx 0.6 (1)
Unknown Primary 4.7 (8)
Overall stage, % (no.)
I 1.2 (2)
II 2.4 (4)
III 9.4 (16)
IV 87.1 (148)
T classification, % (no.)
TX 4.7 (8)
T1 5.9 (10)
T2 15.9 (27)
T3 18.8 (32)
T4 54.7 (93)
N classification, % (no.)
N0 18.8 (32)
N1 11.8 (20)
N2 47.7 (81)
N3 21.8 (37)
Diagnostic method, % (no.)
PET 28.2 (48)
CT 47.6 (81)
Chest x-ray 15.3 (26)
Other 8.8 (15)
Reason for imaging modality, % (no.)
Surveillance 67.6 (115)
Symptomatic 32.4 (55)
Tobacco status, % (no.)
Never 11.8 (20)
Prior 33.5 (57)
Current 54.7 (93)
Palliative chemotherapy, % (no.)
Yes 50 (85)
No 29.4 (50)
Missing data 20.6 (35)
The majority of patients initially presented with advanced T and N
classification, and roughly two-thirds of distant metastasis were detected
on surveillance imaging in patients without symptoms.
SD ¼ standard deviation; PET ¼ positron-emission tomography; CT
¼ computed tomography.
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distant metastases. A P value of <.05 was considered statisti-
cally significant. All statistics were analyzed on SPSS for
Windows version 19.0 (IBM, Armonk, NY) with consultation
from the University of Michigan Center for Statistical Consulta-
tion and Research.
RESULTS
The median life expectancy for the entire cohort af-
ter diagnosis of distant metastasis was 185 days.
Patients who were found on presentation of their head
and neck cancer to have distant metastasis had no dif-
ference in life expectancy compared to those who
developed distant metastasis during follow-up (median,
196 vs. 168 days; P ¼ .754). Patients who underwent a
PET scan as the imaging modality for the diagnosis of
distant metastasis were more likely to be diagnosed with
multiple metastases compared with other imaging modal-
ities (50% vs. 13%; P ¼ .0001). There were no differences
in life expectancy in patients who were diagnosed with dis-
tant metastasis by PET scan versus another imaging
modality (Fig. 1; median 185 vs. 165 days; P ¼ .835).
The development of a single versus multiple sites of
distant metastasis were not predictive of an increased
life expectancy (Fig. 2; median 194 vs. 111 days; P ¼
.148). There were 130 patients with a single metastatic
site and 40 patients with multiple metastatic sites. The
most frequent site in order of decreasing prevalence of
distant metastasis were lung (137), bone (41), liver (22),
dermis (eight), brain (seven), and other (eight). Patients
with less common metastatic sites (bone, dermis, brain,
other) were more likely to be symptomatic (P ¼ .0001).
There was a significant difference in life expectancy
in patients who were discovered to have distant metasta-
sis on routine surveillance imaging compared with
patients who were symptomatic at time of diagnosis
(Fig. 3; median 241 vs. 73 days; P ¼ .001). There were
115 patients who were identified to have distant metas-
tasis by surveillance imaging and 55 patients who had
distant metastasis discovered on imaging due to concern-
ing symptoms. Pulmonary symptoms were the most
common presenting symptom of distant metastasis (31),
followed by skeletal (23).
Bivariate analysis was performed in patients who
had distant metastasis found on surveillance imaging
and who were symptomatic to identify factors within
each group that may increase life expectancy. In the 115
patients who were identified as having distant metasta-
sis by surveillance imaging, 38 (33%) were identified by
PET scan, 57 (50%) by CT scan, and 20 (17%) by chest x-
ray. There were no differences in life expectancy in the
patients who were identified to have distant metastasis
by surveillance imaging when stratified by imaging mo-
dality (Fig. 4a; median 249 vs. 210 vs. 333 days; P ¼
.591). In the 55 patients who were identified as having
distant metastasis discovered on imaging initiated by
concerning symptoms, 10 (18%) were identified by PET
scan, 24 (44%) by CT scan, six (11%) by chest x-ray, and
15 (27%) by other imaging modalities (MRI, bone scan).
There were no differences in life expectancy in the
patients who were identified as having distant metasta-
sis discovered on imaging due to concerning symptoms
when stratified by imaging modality (Fig. 4b; median 49
vs. 102 vs. 43 vs. 73 days; P ¼ .362).
Palliative chemotherapy was offered to patients
who were considered healthy enough to tolerate treat-
ment at the discretion of the medical oncologist and
patient preference. There were 85 (63%) patients who
received palliative chemotherapy, 50 patients who did
not receive palliative chemotherapy, and 35 patients
whose palliative therapy was unknown. These 35
patients typically received care closer to home and did
Fig. 1. Kaplan-Meier (KM) survival curves of the entire cohort
stratified by type of imaging modality. The median life expectancy
of patients who were diagnosed by positron-emission tomography
(PET) scan was 185 days, and for patients who were diagnosed by
other modalities was 165 days (P ¼ .835). [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
Fig. 2. Kaplan-Meier (KM) survival curves of the entire cohort
stratified by the presence of a single versus multiple metastasis.
The median life expectancy of patients who were diagnosed with
a single-site metastasis was 194 days, and for patients who were
diagnosed with multiple site metastasis was 111 days (P ¼ .148).
DM ¼ distant metastasis. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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not return for follow-up. There was a significant differ-
ence in life expectancy in patients who received
palliative chemotherapy compared with those who did
not receive palliative chemotherapy (Fig. 5; median 285
vs. 70; P ¼ .0001). There was no correlation between
type of imaging modality and which patients received
palliative chemotherapy (P ¼ .287).
DISCUSSION
This study suggests that even though PET scan is
more likely to detect multiple metastatic sites, there is
no significant difference in life expectancy based on
imaging modality or the number of metastatic sites. As
expected, patients who are symptomatic from their dis-
tant metastasis had a worse life expectancy, and
palliative chemotherapy was able to increase life expect-
ancy, even in patients who were symptomatic from the
distant metastasis.
PET was first introduced in the 1970s, and
although initially its use was limited by poor resolution
and high cost, improvements in technology and afford-
ability have allowed for rapid expansion of its
indications. Currently, PET scans are widely used in
head and neck cancer management, with studies report-
ing efficacy in pretreatment staging and the detection of
occult primary tumors.4–8 PET has a higher sensitivity
than CT or ultrasound-guided fine-needle aspiration and
a better specificity than MRI in patients with borderline
enlarged cervical lymph nodes, demonstrating an impor-
tant prognostic role in patients who may not have
histopathologic confirmation of their tumors.4
In addition, PET imaging has played an important
role in monitoring local and regional treatment
response,9,10 radiation and surgical treatment planning,
and as examined by our study, surveillance for distant
metastasis.11,12 Although PET has been shown to
accurately detect distant metastasis, the role in surveil-
lance remains unclear. As healthcare costs increase,
providers need to vigilantly justify its use as a tool to
improve patients’ outcomes or change treatment strat-
egies. In this study, we demonstrated that PET had a
greater ability to identify multiple distant metastasis
compared to other imaging modalities, although this did
not translate to a survival benefit. The most common
site for asymptomatic metastases were the lungs,
whereas patients who developed bone, liver, brain, or
other sites of distant metastases were typically identified
by imaging initiated by symptoms. This would suggest
Fig. 3. Kaplan-Meier (KM) survival curves of the entire cohort
stratified by the rationale for obtaining an imaging study. The me-
dian life expectancy of patients who were discovered to have dis-
tant metastasis (DM) on routine surveillance imaging was 241
days, and for patients who were symptomatic at time of diagnosis
was 73 days (P ¼ .001). [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
Fig. 4. (a) Kaplan-Meier (KM) survival curves of patients who had
surveillance imaging stratified by diagnostic imaging modality.
There were no differences in life expectancy in the patients who
were identified as having distant metastasis (DM) by surveillance
imaging when stratified by imaging modality. (b) Kaplan-Meier
survival curves of patients who had symptomatic imaging
stratified by diagnostic imaging modality. There were no
differences in life expectancy in the patients who were identified
as having distant metastasis discovered on imaging initiated
by concerning symptoms when stratified by imaging modality.
PET ¼ positron-emission tomography; CT ¼ computed tomography;
CXR ¼ chest x-ray. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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that in patients who present with symptoms, imaging
modalities that focus on site specific symptoms would be
more efficient than PET. For patients who are asymp-
tomatic, there was no increased life expectancy seen
when stratifying by imaging modality (chest x-ray, CT,
PET). Although stratification by subsite was not per-
formed, and this only represented a subpopulation of
patients, chest x-ray or CT may provide the most cost-
effective screening modality for HNSCC surveillance.
However, cost effectiveness is out of the realm of this
study and warrants further examination.
Chemotherapy is an option for the treatment of
metastatic head and neck cancer, with the objective of
systemic therapy to provide both palliation of symptoms
and lengthen life expectancy. Previous studies have
shown the effectiveness of chemotherapy, with the
majority showing lengthening of the median survival
from 6 to 15 months.13,14 Our results confirm these find-
ings, although there is a selection bias in our study, as
patients must be healthy enough at the time of distant
metastasis diagnosis to receive chemotherapy. Patients
with high ambulatory performance status (Eastern Coop-
erative Oncology Group 0 or 1), poorly differentiated
histology, and previous response to chemotherapy typi-
cally have a better response to palliative chemotherapy.
In contrast, weight loss, poor performance status, prior
radiation therapy, and active smoking have been associ-
ated with a poor prognosis.14–17
The retrospective nature of this study imparts non-
randomization bias, selection bias, and recall bias.
Additionally, it is possible that the difference in life ex-
pectancy based on identification of a distant metastasis
by surveillance imaging compared to symptomatic imag-
ing may be a result of screening patients having distant
metastasis identified earlier (lead time bias). This lead
time bias may confound the results and should be fur-
ther explored.
CONCLUSION
In summary, the identification of distant metastasis
in patients with HNSCC is a devastating event.
Although PET has been shown useful in other clinical
settings, our study demonstrates that PET does not
have the added benefit for prolonging life expectancy in
patients with distant metastasis. Although PET has
been shown useful in other clinical settings, our. The
indications for the use of PET for surveillance or symp-
tomatic imaging of distant metastasis may need to be
reevaluated. Further study into the cost effectiveness of
PET for distant metastasis is necessary to understand
its role in HNSCC.
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